Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
PLoS One. 2022 Jan 21;17(1):e0262571. doi: 10.1371/journal.pone.0262571. eCollection 2022.
Inflammatory bowel disease (IBD) patients often experience disease flare-ups during international air travel. We aimed to identify risk factors associated with IBD flare-up during international air travel.
Patients with scheduled international air travel were enrolled in the study from the Seoul National University Bundang Hospital IBD clinic. Flight information and clinical data were collected via questionnaires and personal interviews, and risk factors associated with IBD flares were determined.
Between May 2018 and February 2020, 94 patients were prospectively enrolled in the study (mean age, 33.0 years; males, 53.2%; mean disease duration, 56.7 months), including 56 (59.6%) with ulcerative colitis and 38 (40.4%) with Crohn's disease. Of the 94 patients enrolled, 15 (16.0%) experienced an IBD flare-up and 79 (84.0%) remained in remission throughout travel. Logistic regression analysis revealed that high fecal calprotectin levels before travel (odds ratio [OR]: 1.001, 95% confidence interval [CI]: 1.000-1.001, p = 0.016), the presence of a comorbidity (OR: 6.334, 95% CI: 1.129-35.526, p = 0.036), and history of emergency room visit (OR: 5.283, 95% CI: 1.085-25.724, p = 0.039) were positively associated with disease flare-up. The previous and current use of immunomodulators and biologics, time of flight, altitude, number countries visited, travel duration, objective of visit, and previous medical consultations were not associated with disease flare-up.
Elevated fecal calprotectin levels, history of emergency room visits, and the presence of a comorbidity predicted IBD flare-up during international air travel.
炎症性肠病(IBD)患者在国际航空旅行中经常会出现疾病发作。本研究旨在确定与国际航空旅行中 IBD 发作相关的危险因素。
从首尔国立大学盆唐医院的 IBD 诊所招募计划进行国际航空旅行的患者。通过问卷和个人访谈收集航班信息和临床数据,并确定与 IBD 发作相关的危险因素。
2018 年 5 月至 2020 年 2 月期间,前瞻性纳入 94 例患者(平均年龄 33.0 岁;男性 53.2%;平均疾病病程 56.7 个月),其中溃疡性结肠炎 56 例(59.6%),克罗恩病 38 例(40.4%)。94 例患者中,15 例(16.0%)出现 IBD 发作,79 例(84.0%)在旅行期间保持缓解。Logistic 回归分析显示,旅行前粪便钙卫蛋白水平较高(比值比 [OR]:1.001,95%置信区间 [CI]:1.000-1.001,p = 0.016)、合并症(OR:6.334,95% CI:1.129-35.526,p = 0.036)和急诊就诊史(OR:5.283,95% CI:1.085-25.724,p = 0.039)与疾病发作呈正相关。免疫调节剂和生物制剂的既往和当前使用、飞行时间、飞行高度、访问国家数量、旅行持续时间、访问目的以及以前的医疗咨询与疾病发作无关。
粪便钙卫蛋白水平升高、急诊就诊史和合并症与国际航空旅行中 IBD 发作相关。